Abstract:IntroductionAcromegaly is a multisystem disease resulting from chronic exposure to supraphysiological levels of growth hormone (GH), and is associated with significant morbidity and excess mortality. The etiology is almost exclusively an underlying pituitary adenoma. Current therapeutic interventions include surgery, radiotherapy, and medical therapy.ResultsDespite surgery, around 50% of patients fail to achieve the biochemical targets shown to correlate with normalization of mortality rates. Radiotherapy is efficacious in controlling tumor growth and GH secretion; still, achievement of biochemical targets may take up to a decade and a number of safety issues have been raised with this treatment modality. Medical therapy, therefore, has an important role as adjuvant therapy in patients who fail to achieve control with surgery, or while awaiting the effects of radiotherapy to be realized. Furthermore, medical therapy is increasingly being used as primary therapy. Current medical therapies include dopaminergic agonists, somatostatin analogs, and GH receptor (GHR) antagonists. Dopaminergic agonists achieve biochemical targets in up to 30% of patients, and somatostatin analogs in around 60%. The currently available GHR antagonist pegvisomant effectively controls insulin-like growth factor-I levels in over 90% of patients; however, it has no effect on the tumor itself and has considerable financial implications. Research into optimizing the somatostatin and dopaminergic systems has led to promising advances in agonist development. Moieties with selectivity for various combinations of somatostatin receptor subtype receptors have been examined, along with molecules that additionally show high affinity for the dopaminergic D2 receptor. Of the molecules studied in vitro, only pasireotide (SOM230) and BIM-23A760 are currently undergoing further development. Other innovations to improve convenience of currently available drugs are also being investigated.ConclusionSignificant advances in under standing of the somatostatin and dopaminergic system have aided drug development. This may lead to new clinically available therapies enabling control of acromegaly in a larger proportion of patients, and at an earlier stage in their disease management.

Pasireotide in the Personalized Treatment of Acromegaly

Predictors of biochemical response to somatostatin receptor ligands in acromegaly

Personalized medicine in acromegaly: The ACROFAST study

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study

Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center

Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis

De-escalation treatment with pasireotide for acromegaly: a long-term experience

Efficacy and Predictors of Short-Term First-Generation Somatostatin Analog Presurgical Treatment in Acromegaly: A Hospital-Based Study of 237 Cases.

Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin

Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis

Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up

Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance

Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly

Current therapy and drug pipeline for the treatment of patients with acromegaly

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly

Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands